Overview

Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

A single-center, single-arm, phase 2 trial of Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion for third-line treatment in patients with colorectal cancer and liver metastases. A total of 30 patients are planned to be enrolled.

Phase:

Phase 2

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University